Inrebic (Fedratinib) is used for the treatment of adult patients with intermediate-2 or high-risk primary/secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Dosage: The recommended inrebic dosage is 400 mg administered orally once daily for patients with a baseline platelet count of greater than or equal to 50 x 109/L. Inrebic dose may be administered with or without food. Administration together with a high fat meal could reduce the incidence of nausea and vomiting. If an inrebic dose is missed, the next scheduled dose should be administered the following day.
Side Effects: The most commonly reported inrebic side effects include:
Warnings and Precautions:
- Baseline testing of thiamine (Vitamin B1) levels should be conducted prior to initiation of inrebic 100 mg therapy.
- Patients taking therapy with ruxolitinib prior to the initiation of fedratinib must taper and interrupted as per the ruxolitinib PI (prescribing information).
- Treatment with fedratinib 100 mg capsules could be responsible for causing thrombocytopenia and anemia. Women of reproductive age should be advised to not become pregnant whilst receiving inrebic 100 mg and should use apt contraception during treatment and for at least 30 days following the last dose.
- Due to the potential for severe side effects in a breastfed child, instruct patients to avoid breastfeeding while on therapy with fedratinib 100 mg, and for minimum 30 days after the last dose.